DOCSLIB.ORG

United States Patent (10) Patent No.: US 7,935,351 B2 Klinman Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
United States Patent (10) Patent No.: US 7,935,351 B2 Klinman Et Al US007935351B2 (12) United States Patent (10) Patent No.: US 7,935,351 B2 Klinman et al. (45) Date of Patent: *May 3, 2011 (54) USE OF CPG OLIGODEOXYNUCLEOTIDES 35. A 3. 2. RS:udolph s et alal. TO INDUCE ANGOGENESIS 5,288,509 A 2f1994 Potman et al. 5.488,039 A 1, 1996 M tal. (75) Inventors: Dennis M. Klinman, Potomac, MD 5.492.899 A 2, 1996 NE al. (US); Mei Zheng, Augusta, GA (US); 5,585,479 A 12/1996 Hoke et al. Barry T. Rouse, Knoxville, TN (US) 5,602,1095,591,721 A 2/19971/1997 MasorAgrawal et etal. al. 5,612,060 A 3, 1997 A1 d (73) Assignees: The United States of America as 5,614,191 A 3, 1997 al represented by the Department of 5,650,156 A 7/1997 Grinstaffet al. Health and Human Services, 5,663,153 A 9, 1997 Hutcerson et al. Washington, DC (US); University of 3. A RE SEE, Tennessee Research Foundation, 5,700,590 A 12/1997 Masoretal Knoxville, TN (US) 5,712.256 A 1/1998 Kulkarni et al. 5,723,335 A 3, 1998 Hutcerson et al. (*) Notice: Subject to any disclaimer, the term of this 3. 2. A 38. El cal patent is extended or adjusted under 35 5.840,705 A 11/1998 Tsukuda U.S.C. 154(b) by 761 days. 5,849,719 A 12, 1998 Carson et al. This patent is Subject to a terminal dis- 33: A 23: SEE claimer. 5,922,766 A 7/1999 Acosta et al. 5,976,580 A 1 1/1999 Ivey et al. (21) Appl. No.: 11/839,217 5,980,958 A 1 1/1999 Naylor et al. 5,994,126 A 11/1999 Stienman et al. (22) Filed: Aug. 15, 2007 6,022,853. A 2/2000 Kuberasampath et al. e - a 9 (Continued) (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2008/OO27021 A1 Jan. 31, 2008 EP O 286 224 10, 1988 Related U.S. Application Data (Continued) (63) Continuation of application No. 10/499.597, filed as application No. PCT/US02/40955 on Dec. 19, 2002, OTHER PUBLICATIONS now Pat. No. 7,615,227. Zheng et al. Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic (60) gyal application No. 60/343,457, filed on Dec. stromal keratitis. Journal of Virology, Oct. 2001, vol. 75, No. 20, pp. s 9828-9835. (51) Int. Cl McGeoch et al. The complete DNA sequence of the long unique Asik 3900 2006.O1 region in the genome of herpes simplex virus type 1. J. Gen. Virol. ( .01) 1988, vol. 69, 1531-1574.* A6 IK39/38 (2006.01) US 6,008,200, Dec. 28, 1999 (withdrawn). A6 IK 45/00 (2006.01) Adya, et al., “Expansion of CREB's DNA recognition specificity by A6 IK 47/00 (2006.01) Tax results from interaction with Ala-Ala-Arg at positions 282-284 AOIN 43/04 (2006.01) near the conserved DNA-binding domain of CREB'. Proc. Natl. (52) U.S. Cl. ............... 424/198.1; 424/1841; 424/278.1; Acad. Sci. USA 91(12):5642-5646 (1994). 514744 R (Continued) (58) Field of Classification Search ........................ None See application file for complete search history. Primary Examiner – N. M. Minnifield (56) References Cited (74) Attorney, Agent, or Firm — Klarduist Sparkman, LLP U.S. PATENT DOCUMENTS (57) ABSTRACT 2,215,233 A 9, 1940 Ruskin 3,906,092 A 9, 1975 Hilleman et al. This disclosure provides a method of inducing production of 3,911,117 A 10, 1975 Ender vascular endothelial growth factor by a cell. The method 3,914.450 A 10, 1975 Robbins et al. 4,469,863. A 9, 1984 Ts'o et al. includes contacting the cell with a CpG oligonucleotide, 4,544.559 A 10, 1985 Gilet al. thereby inducing the production of vascular endothelial 4,741,914 A 5, 1988 Kimizuka et al. growth factor by the cell. The disclosure further provides a 4,758,553 A 7/1988 Ogoshi method inducing neovascularization in a tissue. This method 4,806,376 A 2f1989 Saeki et al. includes comprising introducing a CpG oligodeoxynucle 4.956,296 A 9, 1990 Fahnestock 4,963,387 A 10/1990 Nakagawa et al. otide into an area of the tissue wherein the formation of new 4,994,442 A 2f1991 Gil et al. blood vessels is desired, thereby inducing neovascularization 5,023,243 A 6, 1991 Tullis in the area of the tissue. 5,066,500 A 11, 1991 Gilet al. 5,231,085 A 7, 1993 Alexander et al. 5,234,811 A 8, 1993 Beutler et al. 24 Claims, 6 Drawing Sheets US 7,935,351 B2 Page 2 U.S. PATENT DOCUMENTS 2003/010.0527 A1 5/2003 Krieg et al. 2003/0104044 A1 6/2003 Semple et al. 6, 194,388 B1 2/2001 Krieg et al. 2003. O104523 A1 6, 2003 E. 6,207,646 B1 3/2001 Krieg et al. 2003/0109469 A1 6/2003 Carson et al. 6.214.806 B1 4/2001 Krieg et al. 2003/01 19773 A1 6, 2003 Raz et al. 6.218.371 B1 4/2001 Krieg et al. 2003/01 19774 A1 6, 2003 Foldvariet al. 3. R 299; E. et al 2003/01 19776 A1 6/2003 Phillips et al. 6,406.705 Bi 6/2002 SE A. 2003/O125284 A1 7, 2003 Raz et al. w s 2003/0129251 A1 7, 2003 Van Nest et al. 6.423,539 B2 7/2002 Fong et al. 2003. O130217 A1 7, 2003 Raz et al. 6.428,788 B1 8/2002 Debinski et al. 2003/0.133988 A1 7/2003 Fearon et al. 6,429,199 B1 8/2002 Krieg et al. 2003. O135875 A1 7, 2003 Ehrhardt et al. 6,498,148 B1 12/2002 Raz 2003. O1384.13 A1 7, 2003 Vicari et al. 6,514,948 B1 2/2003 Raz et al. 2003/0138453 A1 7/2003 O'Hagan et al. 6,534,062 B2 3/2003 Raz et al. 2003/0139364 A1 7/2003 Krieg et al. 6,552,006 B2 4/2003 Raz et al. 2003.0143213 A1 7, 2003 Raz et al. 6,562,798 B1 5/2003 Schwartz 2003.0143743 A1 7, 2003 Schuler et al. 6,589,940 B1 7/2003 Raz et al. 2003/0144229 A1 7/2003 Klinman et al. 6,610,661 B1 8/2003 Carson et al. 2003. O14787.0 A1 8, 2003 Raz et al. 6,613,751 B2 9/2003 Raz et al. 2003/0148316 A1 8/2003 Lipford et al. 6,653,292 B 11/2003 Krieg et al. 2003/0148976 A1 8/2003 Krieg et al. 7.354,909 B2 * 4/2008 Klinman et al. 514.44 R 2003/0148983 A1 8/2003 Fontoura etal 7,521,063 B2 * 4/2009 Klinman et al. 424,282.1 2003/015777 Ai 8/2003 Draghia Aki 7,560,436 B2 * 7/2009 Raz et al. ........................ 514,43 2003. O158136 A1 8, 2003 Rice et all 7,615,227 B2 * 1 1/2009 Klinman et al. ........... 424,198.1 2003/065478 A 9/2003 Sokoli 7,666,674 B2 * 2/2010 Klinman et al. .............. 435/375 2003/0166001 A1 9/2003 Lipford 7,758,876 B2 * T/2010 Klinman et al. ........... 424,278.1 2003/0170273 A1 9, 2003 O'Hagan et al. 58-83.3 A. 299; al 2003/0171321 A1 9, 2003 Schmidt et al. get al. 2003/0175731 A1 9, 2003 Fearon et al. 2001/0044416 A1 11/2001 McCluskie et al. 2003/0176373 A1 9, 2003 Raz et al. 2001, 0046967 A1 11, 2001 Van Nest 2003/0176389 A1 9, 2003 Raz et al. 2002fOOO6403 A1 1/2002 Yu et al. 2003/0180320 A1 9/2003 Darju et al. 2002/0028784 A1 3, 2002 Van Nest 2003/0181406 A1 9, 2003 Schetter et al. 2002fOO42383 A1 4, 2002 Yew et al. 2003/0185848 A1 10, 2003 Johnston et al. 2002fOO42387 A1 4, 2002 Raz et al. 2003.0185900 A1 10, 2003 Choi et al. 2002/0055477 A1 5, 2002 Van Nest et al. 2003/0186921 A1 10, 2003 Carson et al. 2002/0064515 A1 5/2002 Krieg et al. 2003/019 1079 A1 10/2003 Krieg et al. 2002/0065236 A1 5, 2002 Yew et al. 2003. O1994.66 A1 10, 2003 F tal 2002fOO86295 A1 7, 2002 Raz et al. eaC ca. 2003/0203861 A1 10, 2003 Carson et al. 2002fOO86839 A1 7, 2002 Raz et al. 2003/0206967 A1 11/2003 Choi et al. 2002/0090724 A1 7/2002 Taylor et al. 2002/009 1095 A1 7/2002 Phillips et al. 2003/02O7287 A1 11/2003 Short 2002/009 1097 A1 7, 2002 Bratzler et al. 2003/0212026 A1 1 1/2003 Krieg et al. 2002/0098199 A1 7, 2002 Van N 1 2003/0212028 A1 11/2003 Raz et al. an Nest et al. 2003/021634.0 A1 11/2003 Van Nest et al. 2002/0098.205 A1 7/2002 Choi et al. 2003/0219752 A1 11/2003 Short 2002fOO98980 A1 7, 2002 Choi et al. 2003,022O277 A1 11/2003 Yew et al. 2002/010.7212 A1 8/2002 Van Nest et al. 2002fO110569 A1 8, 2002 Granoffetal 2003/022401.0 A1 12/2003 Davis et al. ranOffetal. 2003/022501.6 A1 12/2003 Fearon et al. 2002/011 1323 A1 8/2002 Martin et al. 2003/0232780 A1 12/2003 Carson et al. 2002/013.6776 A1 9/2002 Fang et al.
Load more

Recommended publications
  • Human Naive B Cells Cells by Cpg Oligodeoxynucleotide-Primed T+
    Presentation of Soluble Antigens to CD8+ T Cells by CpG Oligodeoxynucleotide-Primed Human Naive B Cells This information is current as Wei Jiang, Michael M. Lederman, Clifford V. Harding and of September 27, 2021. Scott F. Sieg J Immunol 2011; 186:2080-2086; Prepublished online 14 January 2011; doi: 10.4049/jimmunol.1001869 http://www.jimmunol.org/content/186/4/2080 Downloaded from References This article cites 36 articles, 21 of which you can access for free at: http://www.jimmunol.org/content/186/4/2080.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 27, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2011 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Presentation of Soluble Antigens to CD8+ T Cells by CpG Oligodeoxynucleotide-Primed Human Naive B Cells Wei Jiang,*,† Michael M. Lederman,*,† Clifford V. Harding,†,‡ and Scott F. Sieg*,† Naive B lymphocytes are generally thought to be poor APCs, and there is limited knowledge of their role in activation of CD8+ T cells.
    [Show full text]
  • Toll-Like Receptor 9 and 21 Have Different Ligand Recognition Profiles
    Toll-like receptor 9 and 21 have different ligand recognition profiles and cooperatively mediate activity of CpG-oligodeoxynucleotides in zebrafish Da-Wei Yeha,b,1, Yi-Ling Liua,1, Yin-Chiu Loc, Chiou-Hwa Yuhd, Guann-Yi Yuc, Jeng-Fan Loe, Yunping Luof, Rong Xiangg, and Tsung-Hsien Chuanga,h,2 aImmunology Research Center, National Health Research Institutes, Miaoli 35053, Taiwan; bInstitute of Molecular Medicine, National Tsing-Hua University, HsinChu 30013, Taiwan; cNational Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli 35053, Taiwan; dInstitute of Molecular and Genomic Medicine, National Health Research Institutes, Miaoli 35053, Taiwan; eInstitute of Oral Biology, National Yang-Ming University, Taipei 11221, Taiwan; fDepartment of Immunology, School of Basic Medicine, Peking Union Medical College, Beijing 100005, People’s Republic of China; gSchool of Medicine, University of Nankai, Tianjin 300071, People’s Republic of China; and hProgram in Environmental and Occupational Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan Edited by Ken J. Ishii, National Institute of Biomedical Innovation, Ibaraki, Japan, and accepted by the Editorial Board October 29, 2013 (received for review March 21, 2013) CpG-oligodeoxynucleotides (CpG-ODNs) are potent immune stim- containing a GTCGTT motif. In contrast, the GTCGTT motif uli currently under investigation as antimicrobial agents for containing CpG-ODN generates stronger immune responses in different species. Toll-like receptor (TLR) 9 and TLR21 are the humans and various domestic animals (8, 9). cellular receptors of CpG-ODN in mammals and chickens, respec- Toll-like receptors (TLRs) are pattern recognition recep- tively. The avian genomes lack TLR9, whereas mammalian tors that play crucial roles in the initiation of host defense genomes lack TLR21.
    [Show full text]
  • Oligodeoxynucleotide in Murine Asthma Anti-Inflammatory Effects Of
    In Vivo Role of p38 Mitogen-Activated Protein Kinase in Mediating the Anti-inflammatory Effects of CpG Oligodeoxynucleotide in Murine Asthma This information is current as of September 23, 2021. Barun K. Choudhury, James S. Wild, Rafeul Alam, Dennis M. Klinman, Istvan Boldogh, Nilesh Dharajiya, William J. Mileski and Sanjiv Sur J Immunol 2002; 169:5955-5961; ; doi: 10.4049/jimmunol.169.10.5955 Downloaded from http://www.jimmunol.org/content/169/10/5955 References This article cites 37 articles, 21 of which you can access for free at: http://www.jimmunol.org/ http://www.jimmunol.org/content/169/10/5955.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 23, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2002 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology In Vivo Role of p38 Mitogen-Activated Protein Kinase in Mediating the Anti-inflammatory Effects of CpG Oligodeoxynucleotide in Murine Asthma1 Barun K.
    [Show full text]
  • P020210615609549638679.Pdf
    The Journal of Immunology SCARB2/LIMP-2 Regulates IFN Production of Plasmacytoid Dendritic Cells by Mediating Endosomal Translocation of TLR9 and Nuclear Translocation of IRF7 Hao Guo,*,† Jialong Zhang,* Xuyuan Zhang,*,† Yanbing Wang,* Haisheng Yu,*,† Xiangyun Yin,*,† Jingyun Li,*,† Peishuang Du,* Joel Plumas,‡ Laurence Chaperot,‡ ,x,{ ,‖,# , Jianzhu Chen,* Lishan Su,* Yongjun Liu,* ** and Liguo Zhang* Downloaded from Scavenger receptor class B, member 2 (SCARB2) is essential for endosome biogenesis and reorganization and serves as a receptor for both b-glucocerebrosidase and enterovirus 71. However, little is known about its function in innate immune cells. In this study, we show that, among human peripheral blood cells, SCARB2 is most highly expressed in plasmacytoid dendritic cells (pDCs), and its expression is further upregulated by CpG oligodeoxynucleotide stimulation. Knockdown of SCARB2 in pDC cell line GEN2.2 dramatically reduces CpG-induced type I IFN production. Detailed studies reveal that SCARB2 localizes in late endosome/ http://www.jimmunol.org/ lysosome of pDCs, and knockdown of SCARB2 does not affect CpG oligodeoxynucleotide uptake but results in the retention of TLR9 in the endoplasmic reticulum and an impaired nuclear translocation of IFN regulatory factor 7. The IFN-I production by TLR7 ligand stimulation is also impaired by SCARB2 knockdown. However, SCARB2 is not essential for influenza virus or HSV-induced IFN-I production. These findings suggest that SCARB2 regulates TLR9-dependent IFN-I production of pDCs by mediating endosomal translocation of TLR9 and nuclear translocation of IFN regulatory factor 7. The Journal of Immunology, 2015, 194: 4737–4749. ysosomes are ubiquitous acid membrane-bound organelles which also includes scavenger receptor class B, member 1 involved in the degradation of molecules, complexes, and (SCARB1), and CD36 (5).
    [Show full text]
  • Screening of Novel Immunostimulatory Cpg Odns and Their Anti-Leukemic Effects As Immunoadjuvants of Tumor Vaccines in Murine Acute Lymphoblastic Leukemia
    519-529.qxd 20/12/2010 01:05 ÌÌ ™ÂÏ›‰·519 ONCOLOGY REPORTS 25: 519-529, 2011 519 Screening of novel immunostimulatory CpG ODNs and their anti-leukemic effects as immunoadjuvants of tumor vaccines in murine acute lymphoblastic leukemia JIN WANG, WANGGANG ZHANG, AILI HE, WANHONG ZHAO and XINGMEI CAO Department of Hematology, Second Affiliated Hospital, Medical School of Xi'an Jiaotong University, Xi'an 710004, Shaanxi Province, P.R. China Received July 29, 2010; Accepted October 11, 2010 DOI: 10.3892/or.2010.1093 Abstract. Acute lymphoblastic leukemia (ALL) is a common Additional therapeutic strategies are required in order to malignant disease and a major cause of mortality due to further prolong remission duration and eradicate minimal recurrent disease. Immunotherapy is a promising strategy for residual disease, ideally with less toxicity than conventional eradicating minimal residual disease and thus preventing the chemotherapy. One of the these approaches is active immuno- relapse of leukemia. Apart from stem cell transplantation, therapy with novel vaccination regimens. We previously CpG oligodeoxynucleotides (ODNs) are excellent candidates launched a phase-I clinical trial and evaluated the efficacy for the immunotherapy of leukemia. However, the number of and toxicity of vaccination in patients with relapsed or usable CpG ODNs is limited. In this study, we tested a panel refractory acute leukemia, which proved to be a feasible, of CpG ODNs and obtained three CpG ODN sequences with safe, and capable way of eliciting anti-leukemic responses strong immunostimulatory activity by comparing their in vivo (1). capacity to activate lymphocytes. The data revealed that the As tumor cells are considered to be poorly immunogenic, flanking bases, the spacing of individual CpG motifs and poly- it is difficult to elicit an effective specific anti-tumor activity guanosine ends, contribute to the immunostimulatory activity from these cells alone.
    [Show full text]
  • Oligodeoxynucleotide Dendritic Cells to the TLR9 Agonist Cpg Distinct
    Distinct Responses of Lung and Spleen Dendritic Cells to the TLR9 Agonist CpG Oligodeoxynucleotide This information is current as Li Chen, Meenakshi Arora, Manohar Yarlagadda, Timothy of September 24, 2021. B. Oriss, Nandini Krishnamoorthy, Anuradha Ray and Prabir Ray J Immunol 2006; 177:2373-2383; ; doi: 10.4049/jimmunol.177.4.2373 http://www.jimmunol.org/content/177/4/2373 Downloaded from References This article cites 62 articles, 32 of which you can access for free at: http://www.jimmunol.org/content/177/4/2373.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 24, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2006 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Distinct Responses of Lung and Spleen Dendritic Cells to the TLR9 Agonist CpG Oligodeoxynucleotide1 Li Chen,* Meenakshi Arora,* Manohar Yarlagadda,* Timothy B. Oriss,* Nandini Krishnamoorthy,* Anuradha Ray,*† and Prabir Ray2*† Dendritic cells (DCs) sense various components of invading pathogens via pattern recognition receptors such as TLRs.
    [Show full text]
  • Oligonucleotide-Ficoll Conjugate Nanoparticle Adjuvant for Enhanced Immunogenicity of Anthrax Protective Antigen † † † † † † Bob Milley,*, Radwan Kiwan, Gary S
    This is an open access article published under an ACS AuthorChoice License, which permits copying and redistribution of the article or any adaptations for non-commercial purposes. Article pubs.acs.org/bc Optimization, Production, and Characterization of a CpG- Oligonucleotide-Ficoll Conjugate Nanoparticle Adjuvant for Enhanced Immunogenicity of Anthrax Protective Antigen † † † † † † Bob Milley,*, Radwan Kiwan, Gary S. Ott, Carlo Calacsan, Melissa Kachura, John D. Campbell, ‡ † Holger Kanzler, and Robert L. Coffman † Dynavax Technologies Corporation, 2929 Seventh Street, Suite 100, Berkeley, California 94710, United States ‡ MedImmune LLC, One MedImmune Way, Gaithersburg, Maryland 20878, United States ABSTRACT: We have synthesized and characterized a novel phosphorothioate CpG oligodeoxynucleotide (CpG ODN)-Ficoll conjugated nanoparticulate adjuvant, termed DV230-Ficoll. This adjuvant was constructed from an amine-functionalized-Ficoll, a heterobifunctional linker (succinimidyl-[(N-maleimidopropionamido)- hexaethylene glycol] ester) and the CpG-ODN DV230. Herein, we describe the evaluation of the purity and reactivity of linkers of different lengths for CpG-ODN-Ficoll conjugation, optimization of linker coupling, and conjugation of thiol-functionalized CpG to maleimide- functionalized Ficoll and process scale-up. Physicochemical character- ization of independently produced lots of DV230-Ficoll reveal a bioconjugate with a particle size of approximately 50 nm and covalent attachment of more than 100 molecules of CpG per Ficoll. Solutions of purified DV230-Ficoll were stable for at least 12 months at frozen and refrigerated temperatures and stability was further enhanced in lyophilized form. Compared to nonconjugated monomeric DV230, the DV230-Ficoll conjugate demonstrated improved in vitro potency for induction of IFN-α from human peripheral blood mononuclear cells and induced higher titer neutralizing antibody responses against coadministered anthrax recombinant protective antigen in mice.
    [Show full text]
  • Oligodeoxynucleotide Dendritic Cells to the TLR9 Agonist Cpg Distinct
    Distinct Responses of Lung and Spleen Dendritic Cells to the TLR9 Agonist CpG Oligodeoxynucleotide This information is current as Li Chen, Meenakshi Arora, Manohar Yarlagadda, Timothy of September 23, 2021. B. Oriss, Nandini Krishnamoorthy, Anuradha Ray and Prabir Ray J Immunol 2006; 177:2373-2383; ; doi: 10.4049/jimmunol.177.4.2373 http://www.jimmunol.org/content/177/4/2373 Downloaded from References This article cites 62 articles, 32 of which you can access for free at: http://www.jimmunol.org/content/177/4/2373.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 23, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2006 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Distinct Responses of Lung and Spleen Dendritic Cells to the TLR9 Agonist CpG Oligodeoxynucleotide1 Li Chen,* Meenakshi Arora,* Manohar Yarlagadda,* Timothy B. Oriss,* Nandini Krishnamoorthy,* Anuradha Ray,*† and Prabir Ray2*† Dendritic cells (DCs) sense various components of invading pathogens via pattern recognition receptors such as TLRs.
    [Show full text]
  • Toll-Like Receptors As Potential Therapeutic Targets for Multiple Diseases
    REVIEWS TOLL-LIKE RECEPTORS AS POTENTIAL THERAPEUTIC TARGETS FOR MULTIPLE DISEASES Claudia Zuany-Amorim, John Hastewell and Christoph Walker The family of Toll-like receptors (TLRs) is receiving considerable attention as potential regulators and controllers of the immune response through their ability to recognize pathogen-associated molecular patterns. The discovery that endogenous ligands, as well as microbial components, are recognized by TLRs, and that small-molecular-mass synthetic compounds activate TLRs, raised interest in these receptors as potential targets for the development of new therapies for multiple diseases. In this review, we discuss the current and future use of TLR agonists or antagonists in chronic inflammatory diseases and highlight potential problems that are associated with such approaches. 2 INNATE IMMUNITY The immune system has been divided traditionally into PAMPs . The first report of a mammalian TLR and its The early response of a host to an INNATE and ADAPTIVE component, each of which has involvement in host defence — TLR-4 as a receptor for infections by pathogens, such as different roles and functions in defending the organism LIPOPOLYSACCHARIDE (LPS)3 — was followed rapidly by the bacteria and viruses, before the against foreign agents, such as bacteria or viruses. The discovery that the human genome contains several antigen-specific, adaptive innate immune system has developed a series of con- TLRs — ten have been found so far, TLR-1–TLR-10. immune response is induced. served receptors, known as pattern-recognition recep- Members of the TLR family share characteristic extra- ADAPTIVE IMMUNITY tors (PRRs), that recognize specific pathogen-associated cellular and cytoplasmic domains.
    [Show full text]
  • Toll-Like Receptors and Their Potential Roles in Kidney Disease
    J Am Soc Nephrol 15: 854–867, 2004 Signaling Danger: Toll-Like Receptors and their Potential Roles in Kidney Disease HANS-JOACHIM ANDERS,* BERNHARD BANAS,† and DETLEF SCHLO¨ NDORFF* *Nephrological Center, Medizinische Poliklinik, Klinikum der Universität München-Junenstadt, Germany; and †Klinik u. Poliklinik f. Innere Medizin II, Universität Regensburg, Germany. Abstract. Toll-like receptors (TLR) are an emerging family of cells are among the non-immune cells that express TLR1, -2, receptors that recognize pathogen-associated molecular pat- -3, -4, and -6, suggesting that these TLR might contribute to terns and promote the activation of leukocytes and intrinsic the activation of immune responses in tubulointerstitial injury renal cells. Ligands of the TLR include exogenous microbial (e.g., bacterial pyelonephritis, sepsis, and transplant nephrop- components such as LPS (TLR4), lipoproteins and peptidogly- athy). In addition, TLR9 has been shown to be involved in cans (TLR1, -2, -6), viral RNA (TLR3), bacterial and viral antigen-induced immune complex glomerulonephritis and lu- unmethylated cytosin-guanosin dinucleotide (CpG)-DNA pus nephritis by regulating humoral and cellular immune re- (TLR9), and endogenous molecules including heat-shock pro- sponses. TLR are evolutionary conserved regulators of innnate teins and extracellular matrix molecules. Upon stimulation, and adaptive immune reponses. It is likely that TLR are in- TLR induce expression of inflammatory cytokines or costimu- volved in many if not all types of renal inflammation. Here the latory molecules via the MyD88-dependent and MyD88-inde- authors provide an overview on the biology of TLR, summa- pendent signaling pathways shared with the interleukin-1 re- rize the present data on their expression in the kidney, and ceptors.
    [Show full text]
  • Therapeutic Administration of a Synthetic Cpg Oligodeoxynucleotide Triggers Formation of Anti-Cpg Antibodies
    Published OnlineFirst June 27, 2012; DOI: 10.1158/0008-5472.CAN-12-0257 Cancer Priority Report Research Therapeutic Administration of a Synthetic CpG Oligodeoxynucleotide Triggers Formation of Anti-CpG Antibodies Julia Karbach1, Antje Neumann1, Claudia Wahle1, Kathrin Brand1, Sacha Gnjatic2, and Elke Jager€ 1 Abstract The synthetic oligodeoxynucleotide CpG 7909, which contains unmethylated cytosine/guanine (CpG) motifs, has potent immunostimulatory effects when coadministered with NY-ESO-1 peptides or recombinant NY-ESO-1 protein, resulting in an enhanced cellular and humoral immune response against the vaccine antigen. In this study, we report the development of anti-CpG-ODN antibodies in 21 of 37 patients who received CpG 7909 either alone or as a vaccine adjuvant. Specific anti-CpG immunoglobulin G (IgG) antibody titers ranged from 1:400 to 1:100,000. The anti-CpG antibodies cross-reacted with other synthetic CpG-ODNs but not with the DNA of mixed bacterial vaccine and were shown to be phosphorothioate backbone specific. Vaccine-related severe side effects observed in some patients were most likely not related to the development of anti-CpG antibodies. In addition, anti-CpG antibodies did not have negative effects on the vaccine immune response. These results show that anti- CpG antibodies develop in humans against short unmethylated CpG dinucleotide sequences after administration of CpG 7909. Our data therefore substantiate the potency of CpG 7909 to directly stimulate human B-cells and suggest that anti-CpG antibody monitoring should be a part of ongoing and planned clinical trials with CpG- ODNs. Cancer Res; 72(17); 4304–10. Ó2012 AACR. Introduction act on B-cell and monocyte activation.
    [Show full text]
  • Toll-Like Receptor 9 Agonists for Cancer Therapy
    Biomedicines 2014, 2, 211-228; doi:10.3390/biomedicines2030211 OPEN ACCESS biomedicines ISSN 2227-9059 www.mdpi.com/journal/biomedicines/ Review Toll-Like Receptor 9 Agonists for Cancer Therapy Davide Melisi 1,2,*, Melissa Frizziero 2, Anna Tamburrino 1, Marco Zanotto 1, Carmine Carbone 1, Geny Piro 3 and Giampaolo Tortora 2,3 1 Digestive Molecular Clinical Oncology Research Unit, Department of Medicine, University of Verona, 10, Piazzale L.A. Scuro, 37134 Verona, Italy; E-Mails: [email protected] (A.T.); [email protected] (M.Z.); [email protected] (C.C.) 2 Medical Oncology, Azienda Ospedaliera Universitaria Integrata, 10, Piazzale L.A. Scuro, 37134 Verona, Italy; E-Mails: [email protected] (M.F.); [email protected] (G.T.) 3 Laboratory of Oncology and Molecular Therapy, Department of Medicine, University of Verona, 10, Piazzale L.A. Scuro, 37134 Verona, Italy; E-Mail: [email protected] * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +39-45-812-8148; Fax: +39-45-802-7410. Received: 17 April 2014; in revised form: 24 July 2014 / Accepted: 28 July 2014 / Published: 4 August 2014 Abstract: The immune system has acquired increasing importance as a key player in cancer maintenance and growth. Thus, modulating anti-tumor immune mediators has become an attractive strategy for cancer treatment. Toll-like receptors (TLRs) have gradually emerged as potential targets of newer immunotherapies. TLR-9 is preferentially expressed on endosome membranes of B-cells and plasmacytoid dendritic cells (pDC) and is known for its ability to stimulate specific immune reactions through the activation of inflammation-like innate responses.
    [Show full text]